Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
Are Neanderthals descendants of modern humans?
2
The biggest threat to Chernobyl is no longer radiation
3
The man who crawls into the perilous heart of the Chernobyl reactor
4
Collapse of key ocean current may release billions of tonnes of carbon
5
How autoimmune conditions can unexpectedly drive mental illness
6
Werner Herzog searches for ghost elephants in stunning new documentary
7
Is a super El Niño imminent, and what could the impacts be?
8
Stunning photographs show the dynamic patterns of the natural world
9
How to spot the Lyrid meteor shower tonight
10
Surprising male G-spot found in most detailed study of the penis yet
